Literature DB >> 24384012

Neuroinflammation of the central and peripheral nervous system: an update.

O Stüve1, U Zettl.   

Abstract

Inflammatory disorders of the peripheral nervous system (PNS) and central nervous system (CNS) are common, and contribute substantially to physical and emotional disability of affected individuals. Often, the afflicted are young and in their active years. In the past, physicians and scientists often had very little to offer in terms of diagnostic precision and therapeutic effectiveness. During the past two decades, both of these relative shortcomings have clearly improved. Some of the recent developments in clinical neuroimmunology are illustrated in this special edition of Clinical and Experimental Immunology.
© 2014 British Society for Immunology.

Entities:  

Keywords:  autoimmunity; inflammation; neuroimmunology

Mesh:

Year:  2014        PMID: 24384012      PMCID: PMC3927894          DOI: 10.1111/cei.12260

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  9 in total

Review 1.  CLIPPERS: chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders.

Authors:  A Dudesek; F Rimmele; S Tesar; S Kolbaske; P S Rommer; R Benecke; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 2.  Monoclonal antibodies in treatment of multiple sclerosis.

Authors:  P S Rommer; A Dudesek; O Stüve; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 3.  Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls.

Authors:  P Berlit; M Kraemer
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 4.  Myasthenia gravis: an update for the clinician.

Authors:  J P Sieb
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 5.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 6.  Diagnosis, pathogenesis and treatment of myositis: recent advances.

Authors:  P-O Carstens; J Schmidt
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 7.  Paraneoplastic neurological syndromes.

Authors:  F Leypoldt; K-P Wandinger
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 8.  Disease-modifying therapy in multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy: common and divergent current and future strategies.

Authors:  N Melzer; S G Meuth
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

Review 9.  Multiple sclerosis treatment and infectious issues: update 2013.

Authors:  A Winkelmann; M Loebermann; E C Reisinger; U K Zettl
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

  9 in total
  9 in total

Review 1.  Dietary factors in rheumatic autoimmune diseases: a recipe for therapy?

Authors:  Shani Dahan; Yahel Segal; Yehuda Shoenfeld
Journal:  Nat Rev Rheumatol       Date:  2017-04-13       Impact factor: 20.543

2.  The Rapid and Progressive Degeneration of the Cervical Multifidus in Whiplash: An MRI Study of Fatty Infiltration.

Authors:  James M Elliott; D Mark Courtney; Alfred Rademaker; Daniel Pinto; Michele M Sterling; Todd B Parrish
Journal:  Spine (Phila Pa 1976)       Date:  2015-06-15       Impact factor: 3.468

3.  Mechanisms underlying chronic whiplash: contributions from an incomplete spinal cord injury?

Authors:  James M Elliott; Julius P A Dewald; T George Hornby; David M Walton; Todd B Parrish
Journal:  Pain Med       Date:  2014-08-19       Impact factor: 3.750

4.  Pain descriptors of taxane acute pain syndrome (TAPS) in breast cancer patients-a prospective clinical study.

Authors:  Rashi Asthana; Liying Zhang; Bo Angela Wan; Daniela Gallo-Hershberg; Angie Giotis; Mark Pasetka; Jenna van Draanen; Shannon Goodall; Patrick L Diaz; Leah Drost; Edward Chow; Carlo De Angelis
Journal:  Support Care Cancer       Date:  2019-05-17       Impact factor: 3.603

5.  COVID-19 causes neuronal degeneration and reduces neurogenesis in human hippocampus.

Authors:  Amir-Hossein Bayat; Helia Azimi; Meysam Hassani Moghaddam; Vahid Ebrahimi; Mobina Fathi; Kimia Vakili; Gholam-Reza Mahmoudiasl; Mahdi Forouzesh; Mahdi Eskandarian Boroujeni; Zahra Nariman; Hojjat-Allah Abbaszadeh; Arefeh Aryan; Abbas Aliaghaei; Mohammad-Amin Abdollahifar
Journal:  Apoptosis       Date:  2022-07-25       Impact factor: 5.561

Review 6.  Acute and chronic neuropsychiatric symptoms in novel coronavirus disease 2019 (COVID-19) patients: A qualitative review.

Authors:  Calen J Smith; Perry Renshaw; Deborah Yurgelun-Todd; Chandni Sheth
Journal:  Front Public Health       Date:  2022-08-08

Review 7.  Immune-Mediated Diseases from the Point of View of Psychoneuroimmunoendocrinology.

Authors:  Miguel A Ortega; Cielo García-Montero; Oscar Fraile-Martinez; Miguel Angel Alvarez-Mon; Ana Maria Gómez-Lahoz; Guillermo Lahera; Jorge Monserrat; Roberto Rodriguez-Jimenez; Javier Quintero; Melchor Álvarez-Mon
Journal:  Biology (Basel)       Date:  2022-06-28

Review 8.  New Therapeutic Approaches to and Mechanisms of Ginsenoside Rg1 against Neurological Diseases.

Authors:  Yang Sun; Yantao Yang; Shasha Liu; Songwei Yang; Chen Chen; Meiyu Lin; Qi Zeng; Junpeng Long; Jiao Yao; Fan Yi; Lei Meng; Qidi Ai; Naihong Chen
Journal:  Cells       Date:  2022-08-16       Impact factor: 7.666

9.  Cardiac Autonomic Dysfunction in Myasthenia Gravis and Relapsing-Remitting Multiple Sclerosis-A Pilot Study.

Authors:  Łukasz Rzepiński; Monika Zawadka-Kunikowska; Julia L Newton; Paweł Zalewski
Journal:  J Clin Med       Date:  2021-05-18       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.